Connection

Jacobo Mintzer to Alzheimer Disease

Back to Details
This is a "connection" page, showing publications Jacobo Mintzer has written about Alzheimer Disease.
Jacobo Mintzer
Connection Strength
9.460
Alzheimer Disease
  1. Dementia in the incarcerated population: a retrospective study using the South Carolina Alzheimer's disease registry, USA. Int J Prison Health. 2023 02 27; ahead-of-print(ahead-of-print).
    View in: PubMed
    Score: 0.605
  2. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021 11 01; 78(11):1324-1332.
    View in: PubMed
    Score: 0.552
  3. Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. Am J Geriatr Psychiatry. 2021 01; 29(1):81-89.
    View in: PubMed
    Score: 0.499
  4. A retrospective, population-based cohort study of driving under the influence, Alzheimer's disease diagnosis, and survival. Int Psychogeriatr. 2019 04; 31(4):571-577.
    View in: PubMed
    Score: 0.446
  5. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. Int Psychogeriatr. 2014 Feb; 26(2):239-46.
    View in: PubMed
    Score: 0.317
  6. Depression in Alzheimer's disease: consequence or contributing factor? Expert Rev Neurother. 2011 Nov; 11(11):1501-3.
    View in: PubMed
    Score: 0.276
  7. Establishment of a predominantly African-American cohort for the study of Alzheimer's disease: the South Carolina Alzheimer's disease clinical core. Dement Geriatr Cogn Disord. 2009; 27(4):329-36.
    View in: PubMed
    Score: 0.230
  8. Using risperidone for Alzheimer's dementia-associated psychosis. Expert Opin Pharmacother. 2008 Oct; 9(14):2537-43.
    View in: PubMed
    Score: 0.223
  9. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clin Drug Investig. 2008; 28(5):291-303.
    View in: PubMed
    Score: 0.211
  10. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007 Nov; 15(11):918-31.
    View in: PubMed
    Score: 0.209
  11. Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. Int Psychogeriatr. 2007 Jun; 19(3):539-58.
    View in: PubMed
    Score: 0.202
  12. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006 Mar; 14(3):280-91.
    View in: PubMed
    Score: 0.186
  13. Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Dis Assoc Disord. 2005 Jan-Mar; 19(1):37-40.
    View in: PubMed
    Score: 0.172
  14. Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets. 2004 Aug; 5(6):517-28.
    View in: PubMed
    Score: 0.167
  15. Assessing current practice in Alzheimer's disease. CNS Spectr. 2004 Jul; 9(7 Suppl 5):5.
    View in: PubMed
    Score: 0.166
  16. What are the challenges faced by psychiatrists in the management of Alzheimer's disease? CNS Spectr. 2004 Jul; 9(7 Suppl 5):13-5.
    View in: PubMed
    Score: 0.166
  17. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int J Geriatr Psychiatry. 2003 Apr; 18(4):292-7.
    View in: PubMed
    Score: 0.152
  18. The search for better noncholinergic treatment options for Alzheimer's disease. J Clin Psychiatry. 2003; 64 Suppl 9:18-22.
    View in: PubMed
    Score: 0.150
  19. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. Int J Geriatr Psychiatry. 2001 Dec; 16 Suppl 1:S71-7.
    View in: PubMed
    Score: 0.139
  20. Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis. J Intern Med. 2021 08; 290(2):310-334.
    View in: PubMed
    Score: 0.132
  21. Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. Am J Geriatr Psychiatry. 2021 01; 29(1):51-62.
    View in: PubMed
    Score: 0.124
  22. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimers Dement. 2019 11; 15(11):1427-1436.
    View in: PubMed
    Score: 0.119
  23. Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation. Biol Psychiatry. 1998 Nov 01; 44(9):918-21.
    View in: PubMed
    Score: 0.112
  24. Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2018 11; 33(7):450-457.
    View in: PubMed
    Score: 0.109
  25. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018 Jan 18; 19(1):46.
    View in: PubMed
    Score: 0.106
  26. Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations. Am J Psychiatry. 2017 04 01; 174(4):362-369.
    View in: PubMed
    Score: 0.098
  27. Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of?Alzheimer's Disease. J Alzheimers Dis. 2016 08 10; 54(1):373-81.
    View in: PubMed
    Score: 0.096
  28. Zolpidem for the treatment of agitation in elderly demented patients. J Clin Psychiatry. 1996 Aug; 57(8):372-3.
    View in: PubMed
    Score: 0.096
  29. Alzheimer's disease and managed care: challenges and strategies. J S C Med Assoc. 1996 Jun; 92(6):255-60.
    View in: PubMed
    Score: 0.095
  30. Principal components analysis of agitation outcomes in Alzheimer's disease. J Psychiatr Res. 2016 08; 79:4-7.
    View in: PubMed
    Score: 0.094
  31. Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. Am J Psychiatry. 2016 May 01; 173(5):473-80.
    View in: PubMed
    Score: 0.094
  32. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. Am J Psychiatry. 2016 May 01; 173(5):465-72.
    View in: PubMed
    Score: 0.092
  33. Cross-cultural perspectives: agitation in demented patients in the United States. Int Psychogeriatr. 1996; 8 Suppl 3:487-90; discussion 491-2.
    View in: PubMed
    Score: 0.092
  34. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. J Psychiatr Res. 2016 Mar; 74:17-21.
    View in: PubMed
    Score: 0.092
  35. A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. J Pharmacokinet Pharmacodyn. 2016 Feb; 43(1):99-109.
    View in: PubMed
    Score: 0.091
  36. The neural correlates of anomia in the conversion from mild cognitive impairment to Alzheimer's disease. Neuroradiology. 2016 Jan; 58(1):59-67.
    View in: PubMed
    Score: 0.090
  37. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20; 85(16):1383-91.
    View in: PubMed
    Score: 0.090
  38. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA. 2015 Sep 22-29; 314(12):1242-54.
    View in: PubMed
    Score: 0.090
  39. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015 Dec; 27(12):2059-67.
    View in: PubMed
    Score: 0.090
  40. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. J Geriatr Psychiatry Neurol. 2016 Mar; 29(2):59-64.
    View in: PubMed
    Score: 0.090
  41. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. Am J Geriatr Psychiatry. 2015 Nov; 23(11):1127-33.
    View in: PubMed
    Score: 0.088
  42. New approaches in the treatment of Alzheimer's disease. J S C Med Assoc. 1994 Nov; 90(11):553-9.
    View in: PubMed
    Score: 0.085
  43. Induction of salivary nerve growth factor by Yogic breathing: a randomized controlled trial. Int Psychogeriatr. 2015 Jan; 27(1):168-70.
    View in: PubMed
    Score: 0.084
  44. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS One. 2014; 9(6):e98426.
    View in: PubMed
    Score: 0.083
  45. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014 Feb 19; 311(7):682-91.
    View in: PubMed
    Score: 0.081
  46. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. Am J Geriatr Psychiatry. 2014 Jan; 22(1):14-24.
    View in: PubMed
    Score: 0.080
  47. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014 Jan 01; 311(1):33-44.
    View in: PubMed
    Score: 0.080
  48. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013 Aug; 74(8):810-6.
    View in: PubMed
    Score: 0.078
  49. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimers Dement. 2014 Jan; 10(1):36-44.
    View in: PubMed
    Score: 0.076
  50. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry. 2012 Dec; 20(12):1036-44.
    View in: PubMed
    Score: 0.074
  51. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012 Oct 18; 367(16):1497-507.
    View in: PubMed
    Score: 0.074
  52. Exploratory analysis of seven Alzheimer's disease genes: disease progression. Neurobiol Aging. 2013 Apr; 34(4):1310.e1-7.
    View in: PubMed
    Score: 0.073
  53. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2012 Sep; 27(6):421-32.
    View in: PubMed
    Score: 0.073
  54. Daughters caregiving for Hispanic and non-Hispanic Alzheimer patients: does ethnicity make a difference? Community Ment Health J. 1992 Aug; 28(4):293-303.
    View in: PubMed
    Score: 0.073
  55. The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. Am J Geriatr Psychiatry. 2012 Apr; 20(4):362-73.
    View in: PubMed
    Score: 0.071
  56. Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement. 2012; 8(2):121-30.
    View in: PubMed
    Score: 0.070
  57. Sertraline for the treatment of depression in Alzheimer disease: genetic influences. J Geriatr Psychiatry Neurol. 2011 Dec; 24(4):222-8.
    View in: PubMed
    Score: 0.069
  58. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ? 2 (DIADS-2)? Int J Geriatr Psychiatry. 2011 Jun; 26(6):573-83.
    View in: PubMed
    Score: 0.067
  59. Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology. 2011 Mar; 258(3):843-52.
    View in: PubMed
    Score: 0.065
  60. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010 Apr; 18(4):332-40.
    View in: PubMed
    Score: 0.062
  61. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010 Feb; 18(2):136-45.
    View in: PubMed
    Score: 0.061
  62. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement. 2008 Mar; 4(2):65-79.
    View in: PubMed
    Score: 0.053
  63. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008 Feb; 5(1):83-9.
    View in: PubMed
    Score: 0.053
  64. The many faces of psychosis in the elderly. Curr Opin Psychiatry. 2007 Nov; 20(6):551-8.
    View in: PubMed
    Score: 0.052
  65. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007 May; 22(5):475-84.
    View in: PubMed
    Score: 0.050
  66. Preliminary examination of progression of Alzheimer's disease in a rural Southern African American cohort. Arch Clin Neuropsychol. 2007 Mar; 22(3):405-14.
    View in: PubMed
    Score: 0.050
  67. Design of Depression in Alzheimer's Disease Study-2. Am J Geriatr Psychiatry. 2006 Nov; 14(11):920-30.
    View in: PubMed
    Score: 0.049
  68. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006 Sep; 14(9):767-76.
    View in: PubMed
    Score: 0.048
  69. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005 Nov; 13(11):942-9.
    View in: PubMed
    Score: 0.045
  70. Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'. Int J Geriatr Psychiatry. 2005 Feb; 20(2):119-27.
    View in: PubMed
    Score: 0.043
  71. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004 Jan; 19(1):9-18.
    View in: PubMed
    Score: 0.040
  72. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66.
    View in: PubMed
    Score: 0.040
  73. Psychosis in elderly patients: classification and pharmacotherapy. J Geriatr Psychiatry Neurol. 2003 Dec; 16(4):199-206.
    View in: PubMed
    Score: 0.040
  74. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry. 2003 Nov; 160(11):2003-11.
    View in: PubMed
    Score: 0.040
  75. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001 Nov; 71(5):589-95.
    View in: PubMed
    Score: 0.034
  76. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 1999 Apr 12; 52(6):1146-52.
    View in: PubMed
    Score: 0.029
  77. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. Br J Clin Pharmacol. 2016 09; 82(3):784-92.
    View in: PubMed
    Score: 0.024
  78. The occurrence of different intrusive errors in patients with Alzheimer's disease, multiple cerebral infarctions, and major depression. Brain Cogn. 1991 May; 16(1):104-17.
    View in: PubMed
    Score: 0.017
  79. Acute desensitization of lymphocyte beta-adrenergic-stimulated adenylate cyclase in old age and Alzheimer's disease. Life Sci. 1984 Oct 22; 35(17):1795-802.
    View in: PubMed
    Score: 0.011
  80. Dementia with Lewy bodies. Lancet Neurol. 2004 Jan; 3(1):19-28.
    View in: PubMed
    Score: 0.010
  81. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999 Feb; 60(2):107-15.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.